Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Skin Neoplasms

Micronutrients

Vasodilator Agents

Lipid Regulating Agents

All Drugs and Chemicals

Hematinics

Vitamins

Niacin

Nicotinic Acids

Niacinamide

Hypolipidemic Agents

Antimetabolites

Folic Acid

Vitamin B Complex

Trace Elements

Nicotinic Acid

Vitamin B3

Nicotinamide

Folate

Vitamin B9

Participants apply topical myristyl nicotinate to the right forearm and topical placebo to the left forearm once daily for 4 weeks; Myristyl (Right), Placebo (Left) Topical Myristyl Nicotinate Cream and Placebo

Participants apply topical myristyl nicotinate to the left forearm and topical placebo to the right forearm once daily for 4 weeks; Myristyl (Left), Placebo (Right)Topical Myristyl Nicotinate Cream and Placebo

Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.

Topical Myristyl Nicotinate Cream

Participants apply topical placebo to one forearm once daily for 4 weeks.

Placebo

Clara Curiel, MD

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of topical myristyl nicotinate cream may stop skin cancer from forming.

PURPOSE: This randomized phase I trial is studying the side effects and best way to give topical myristyl nicotinate cream on the skin of healthy volunteers.

OBJECTIVES:

* To determine if topical myristyl nicotinate (MN) is a safe, tolerable treatment in healthy volunteers.
* To determine if topically administered MN cream is associated with any significant local or systemic toxicity in normal human subjects in a one-month period.

OUTLINE: Participants are randomized to 1 of 2 treatment arms and serve as their own controls.

* Arm I: Participants apply topical myristyl nicotinate to one forearm and topical placebo to the other forearm once daily for 4 weeks.
* Arm II: Participants receive treatment as in arm I but on opposite forearms. All participants undergo blood collection for chemistry analysis (SMA-20 and CBC) at baseline and at 2 and 4 weeks.

Topical Myristyl Nicotinate Cream on the Skin of Healthy Volunteers

A Phase I Study of Topical Myristyl Nicotinate Cream on Human Skin in Healthy Volunteers

Comparison of number of participants with adverse events by treatment.

National Cancer Institute (NCI)

University of Arizona

Forearms receiving the Myristyl and Placebo, both arms affected

Both Forearms

Placebo Forearm (Only)

Myristyl Forearm (Only)

Systemic Other Adverse Events, i.e. Common Cold, Migraine

Other Non-Derm Events

Participants apply topical myristyl nicotinate to the and topical placebo to the other forearm once daily for 4 weeks; Myristyl, Placebo

Topical Myristyl Nicotinate Cream and Placebo : Applied topically

Myristyl, Placebo

Age, Categorical

Age, Continuous

Sex: Female, Male

United States

Region of Enrollment

Steve Stratton,PhD Chairman of Scientific Review Comittee

Participants apply topical myristyl nicotinate to one forearm.

Myristyl Nicotinate Cream

Participants apply topical placebo cream to one forearm.

Topical Placebo Cream

Participants With Adverse Events by Treatment.

Participants apply topical myristyl nicotinate to the right forearm and topical placebo to the left forearm once daily for 4 weeks; Myristyl (Right), Placebo (Left)Topical Myristyl Nicotinate Cream and Placebo

Topical Myristyl Nicotinate Cream and Placebo : Applied topically

Spots Global Cancer Trial Database for topical myristyl nicotinate cream